BioCryst Pharmaceuticals, Inc.
BCRX
$8.73
$0.789.81%
NASDAQ
| 03/31/2025 | 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | |
|---|---|---|---|---|---|
| Revenue | 145.53M | 131.53M | 117.09M | 109.33M | 92.76M |
| Total Other Revenue | -- | -- | -- | -- | 3.89M |
| Total Revenue | 145.53M | 131.53M | 117.09M | 109.33M | 92.76M |
| Cost of Revenue | 41.84M | 55.57M | 44.31M | 39.36M | 47.76M |
| Gross Profit | 103.70M | 75.96M | 72.78M | 69.98M | 45.00M |
| SG&A Expenses | 82.47M | 80.47M | 65.08M | 61.21M | 59.49M |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 124.31M | 136.04M | 109.39M | 100.57M | 107.25M |
| Operating Income | 21.23M | -4.51M | 7.69M | 8.76M | -14.49M |
| Income Before Tax | 758.00K | -25.99M | -13.45M | -12.50M | -35.01M |
| Income Tax Expenses | 726.00K | 804.00K | 586.00K | 172.00K | 365.00K |
| Earnings from Continuing Operations | 32.00K | -26.80M | -14.03M | -12.67M | -35.38M |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | 32.00K | -26.80M | -14.03M | -12.67M | -35.38M |
| EBIT | 21.23M | -4.51M | 7.69M | 8.76M | -14.49M |
| EBITDA | 21.56M | -2.43M | 8.00M | 9.08M | -14.18M |
| EPS Basic | 0.00 | -0.13 | -0.07 | -0.06 | -0.17 |
| Normalized Basic EPS | 0.00 | -0.08 | -0.04 | -0.04 | -0.11 |
| EPS Diluted | 0.00 | -0.13 | -0.07 | -0.06 | -0.17 |
| Normalized Diluted EPS | 0.00 | -0.08 | -0.04 | -0.04 | -0.11 |
| Average Basic Shares Outstanding | 208.88M | 207.38M | 206.91M | 206.43M | 206.06M |
| Average Diluted Shares Outstanding | 215.26M | 207.38M | 206.91M | 206.43M | 206.06M |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |